Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Trial Details

NCT ID

NCT06532643

Phase

EARLY_PHASE1

Sponsor

Shanghai First Song Biotechnology Co., LTD

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• anti-CD20/CD30-CAR-T cells
• Fludarabine
• Cyclophosphamide

Locations (sample)

• Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

• Patients must meet all of the following criteria to be eligible for the study:
• Voluntarily participate in the clinical study. The individual or the legal guardian fully understands the study, sign the informed consent form (IC…
• Age ≥ 14 years and \< 70 years.
• Subjects with refractory or relapsed disease after current standard treatments (including allogeneic or autologous hematopoietic stem cell transpla…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.